IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Emmanuel CONSEILLER, et al.

Appl. No.: 09/829,936

Filed:

April 11, 2001

For:

POLYPEPTIDE (MBP1) CAPABLE OF

INTERACTING WITH ONCOGENIC MUTANTS OF THE P53 PROTEIN

BOX MISSING PARTS

Commissioner for Patents Washington, D.C. 20231

Sir:

Art Unit: 1646

Examiner: Unassigned

TECH CENTER 1200 TOOS

RESPONSE TO NOTICE TO COMPLY WITH SEQUENCE REQUIREMENTS IN ACCORDANCE WITH 37 C.F.R. §§ 1.821-1.825

In response to the Notice mailed November 30, 2001 (copy enclosed), Applicants submit a substitute Computer Readable Form (CRF) copy and a paper copy of Sequence Listing. The undersigned hereby states that:

- 1. the submission, filed herewith in accordance with 37 C.F.R. § 1.821(g), does not include new matter; and
- 2. the content of the attached paper copy and the attached computer readable form copy of the Sequence Listing, submitted in accordance with 37 C.F.R. § 1.821(c) and (e), respectively, are the same.

If any fees, petition, or request for extension of time is required to enter this paper, Applicants hereby request them and the Commissioner is hereby authorized to charge the fees required to Deposit Account No. 50-1129.

Respectfully submitted,

WILEY REIN & FIELDING LLP

Date: January 29, 2002

David J. Kulik; Reg. No. 36,576

Wiley Rein & Fielding LLP 1776 K Street, N.W. Washington, D.C. 20006 202.719.7000 (Telephone) 202.719.7049 (Facsimile)